Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pegbelfermin - Bristol-Myers Squibb

Drug Profile

Pegbelfermin - Bristol-Myers Squibb

Alternative Names: ARX-618; BMS 986036; FGF-21 mimetic proteins; PEG-FGF21; Pegbelfermin; Pegylated FGF21; Pegylated-fibroblast growth factor-21

Latest Information Update: 13 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ambrx
  • Developer Bristol-Myers Squibb
  • Class Antifibrotics; Antihyperglycaemics; Fibroblast growth factors; Hepatoprotectants; Obesity therapies; Polyethylene glycols; Proteins
  • Mechanism of Action Fibroblast growth factor replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Fibrosis; Liver disorders; Non-alcoholic steatohepatitis; Type 2 diabetes mellitus

Most Recent Events

  • 07 Mar 2024 Ambrx has been acquired by Johnson & Johnson
  • 10 Nov 2023 Efficacy data from a phase II trial in Nonalcoholic Steatohepatitis resented at the 74th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2023)
  • 02 Jun 2022 Bristol-Myers Squibb completes a phase I trial in Liver disorders (In Adults) in USA (NCT04634149)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top